Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 212Irinotecan 145Leucovorin 139Gemcitabine 124S 1 (combination) 110apatinib 109Cisplatin 102Drug Therapy 98Bevacizumab 98Radiotherapy 97Paclitaxel 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 53toripalimab 52Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × BID protein, human × Gastrointestinal × Clear all
NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Affiliated Hospital of Qinghai University

Phase 2 Unknown
31 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡